Research Areas

Long-Term Effects of Insulin plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients with Type 2 Diabetes: A Comparison of Premeal investigational insulin to a Once-Daily Insulin Glargine

A Phase 3, Randomized, Double-blind, Placebo Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of an investigational medication in Combination with Metformin Therapy in Subjects with Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover Study With an investigational medication in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin

A Phase IIb, Randomized, Place-Controlled, Dose-Range Finding Clinical Trial to Study the Safety and Efficacy of An Investigational Medication in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control

A Phase 2, Multicenter, Randomized, Double Blind, Parallel Group, Placebo-Controlled Study of An Investigational Medication in Subjects With Type 2 Diabetes and Inadequate Glycemic Control With Metformin Therapy

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase II Study of An Investigational Medication in Patients with Type 2 Diabetes Mellitus

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Safety and Efficacy Study of An Investigational Medication (10 mg and 25 mg administered orally once daily) During 52 Weeks in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control on MDI Insulin Regimen Alone or With Metformin

A Trial Comparing the Efficacy and Safety of An Investigational Insulin (200 U/mL) and An Investigational Insulin (100 U/mL) in Subjects with Type 2 Diabetes Mellitus

Phase 1/2A, Randomized, Double-Bind, Placebo-Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of An Investigational Injection Following Single and Multiple Ascending Subcutaneous Doses in Adult Subjects with Type 2 Diabetes Mellitus

Safety and Efficacy of an investigational medication in Patients with Type 1 Diabetes Mellitus

A Phase 1 Study in Patients with Type 1 Diabetes Mellitus to Evaluate the Single and Multiple Dose Pharmacokinetics and Safety of An Investigational Medication After Subcutaneous Administration

Collection of Blood Samples from Normal Subjects for the Development of a Multiple Sclerosis Biomarker IVD

A Randomized, Double-Blinded, Placebo-Controlled, Single-dose, Dose-escalating Study Of An Investigational Medication in Postmenopausal Women with Osteoporosis

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an investigational medication in Obese Patients

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety, Tolerability, and Efficacy of an investigational medication in Maintaining Weight Loss Induced by a Very Low Calorie Diet in Obese Patients

Effect of An Investigational Medication on Body Weight in Non-Diabetic Obese Subjects or Overweight Subjects With Comorbidities: A Randomized, Double Blind, Placebo Controlled, Parallel Group, Multicentre, Multinational Trial with Stratification of Subject to Either One or Three Years of Treatment Based on Pre-Diabetes Status at Randomization.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Study of An Investigational Medication (10mg and 25mg administered once daily) As Add on to Pre-Existing Antidiabetic Therapy Over 52 Weeks in Patients with Type 2 Diabetes Mellitus and Renal Impairment and Insufficient Glycemic Control

A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of An Investigational Medication to Placebo in Subjects with Diabetic Neuropathic Pain

A 90-Day, Randomized, Dose-Ranging Study, Including Potential Dose Titration, Evaluating the Efficacy and Safety of An Intranasal Investigational Medication in the Treatment of Male Hypogonadism with Sequential Safety Extension Periods of 90 and 180 Days

Phase 1, Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Response of An Investigational Injection Following a Single Subcutaneous Doses in Adult Subjects with Stage 1 or Stage 2 Essential Hypertension